ClinicalTrials.gg
CompletedNCT06774859Updated Apr 27, 2026Results posted

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

A Phase 3 interventional study of Baloxavir Marboxil and Oseltamivir in Influenza, sponsored by Hoffmann-La Roche. Completed at 16 sites in China. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
16th of 18
100 · median 483
Started
2024
with 1 other
Phase 3
12 of 18
5 open now
Registered
16th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 12 in phase 3, and was the 16th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to \< 12 years with influenza symptoms.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A participant who has a diagnosis of influenza virus infection and meets all the following conditions:

    • Fever ≥ 38°C (tympanic temperature) at screening
    • At least one of the respiratory symptoms of influenza virus infection
  • A rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) shows positive for influenza A/B, e.g., point-of-care/local laboratory results with use of nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)
  • The time interval between the onset of symptoms and screening is ≤ 48 hours
  • PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care/local laboratory test with nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)

Exclusion criteria

Exclusion Criteria:

  • A participant having severe influenza virus infection symptoms requiring inpatient treatment
  • Received systemic or therapy
  • Primary immunodeficiency syndrome
  • History of organ transplantation
  • (HIV) infection
  • Immunization with a live/attenuated influenza vaccine in 2 weeks prior to randomization
  • Previous within the last 5 years or has an active cancer at any site
  • A participant who received any medications with anti-flu effect such as baloxavir, peramivir, oseltamivir, zanamivir, favipiravir, arbidol, amantadine or traditional Chinese anti-influenza medicines within 30 days before screening
  • Diagnosed with or suspected SARS-CoV-2 infection, or close contacts of diagnosed or suspected SARS-CoV-2 infected patients
  • Severe underlying disease or condition potentially affecting study evaluation in the opinion of the investigator/sub-investigator
  • A participant who received an or unapproved drug product within 30 days or 5 x the half-life before screening, whichever is longer
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants will receive a single oral dose of baloxavir marboxil on Day 1 based on body weight.

    Drug: Baloxavir Marboxil

  • Active comparator
    Oseltamivir

    Participants will receive oseltamivir twice a day for 5 days based on body weight.

    Drug: Oseltamivir

Interventions

  • Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).

  • Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, was a congenital anomaly or birth defect.

    Time frame: Up to Day 29

Secondary outcomes

  1. Time to Alleviation of Influenza Signs and Symptoms (TTAS)

    TTAS was defined as the length of time taken from start of treatment to point at which all of following criteria were met \& remained so for at least 21.5 hours: * Score of 0 (no problem) or 1 (minor problem) for cough \& nasal symptoms (Items 14 \& 15 of Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to following question- "Since last assessment has participant been able to return to day care/school, or resume his/her normal daily activity in same way as performed prior to developing flu?"; * Return to afebrile state (tympanic temperature ≤ 37.2 degree Celsius \[°C\]). Median time was estimated using Kaplan-Meier (K-M) method.

    Time frame: Up to Day 15

  2. Duration of Fever

    Duration of fever was defined as the length of time from start of treatment to return to afebrile state (tympanic temperature ≤ 37.2°C) and remaining so for at least 21.5 hours. Participants who were afebrile at baseline (tympanic temperature ≤ 37.2 °C) or whose body temperature was not collected were excluded from the analysis. Median time was estimated using K-M method.

    Time frame: Up to Day 15

  3. Duration of Symptoms

    Duration of symptoms was defined as the length of time from start of treatment to alleviation of all symptoms as defined by a score of 0 (no problem) or 1 (minor problem) and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point. Median time was estimated using K-M method.

    Time frame: Up to Day 15

  4. Time to Return to Normal Health and Activity Based on the CARIFS Questionnaire

    Time to return to normal health and activity was defined as time from start of treatment to normal health and activity. Normal health \& activity was identified by a 'yes' response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his/her normal daily activity in the same way as performed prior to developing the flu?". Median time was estimated using K-M method.

    Time frame: Up to Day 15

  5. Number of Participants With Influenza-related Complications

    Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis.

    Time frame: Up to Day 29

  6. Percentage of Participants Requiring Antibiotics for Influenza-related Complications

    Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis. Percentages have been rounded off.

    Time frame: Up to Day 29

  7. Time to Cessation of Viral Shedding by Virus Titer

    Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of study treatment and the first time when the influenza virus titer was below the lower limit of detection (LLoD) (0.75 log10 tissue culture infectious dose \[TCID\] 50/milliliters \[mL\]). Participants whose virus ribonucleic acid (RNA) did not reach the limit by the last observation timepoint were treated as censored at that timepoint. Median time was estimated using K-M method.

    Time frame: Up to Day 29

  8. Time to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs

    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of study treatment and the first time when the virus RNA by RT-PCR qualitative result is below the LLoD (qualitative assessment). For the participants with multiple virus types, time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result is negative for all virus types. Participants whose virus RNA did not reach the limit by the last observation timepoint were censored at that timepoint. Median time was estimated using K-M method.

    Time frame: Up to Day 29

  9. Change From Baseline in Influenza Virus Titer Over Time Using Samples From Respiratory Swabs

    Change from baseline in influenza virus titer (log10 TCID50/mL) on Days 2, 4, 6, 10, and 15 are presented. Influenza virus titer on specified time points was analysed with use of samples from respiratory swabs. If influenza virus titer was less than the lower limit of quantification (LLoQ), the virus titer was imputed as LLoQ - 0.001 (0.749 log10 TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.

    Time frame: Baseline, Days 2, 4, 6, 10, and 15

  10. Change From Baseline in Amount of Virus RNA (RT-PCR) at Each Timepoint Using Samples From Respiratory Swabs

    If the amount of virus RNA was less than the LLoQ, the amount of virus RNA was imputed as LLoQ - 0.001 (2.79 log10 vp/mL for influenza A and 2.63 log10 vp/mL for influenza B). If a participant was infected with multiple virus types, the sum of those amounts of virus RNA was used for analysis. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. log10 vp/mL=log 10 virus particles per milliliter.

    Time frame: Baseline, Days 2, 4, 6, 10, and 15

  11. Percentage of Participants With Positive Influenza Virus Titer Over Time

    Percentage of participants with positive influenza virus titer was defined as the percentage of participants whose influenza virus titer was not less than the LLoD (0.75 log10 TCID50/mL) or positive among those assessed for influenza virus titer on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants with a positive influenza virus titer on Day 1 were be included in this analysis. Percentages have been rounded off.

    Time frame: Baseline, Days 2, 4, 6, 10, and 15

  12. Percentage of Participants Positive by RT-PCR at Each Timepoint Using Samples From Respiratory Swabs

    Percentage of participants with positive influenza virus titer was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants positive for virus RNA by RT-PCR on Day 1 were be included in this analysis. Percentages have been rounded off.

    Time frame: Baseline, Days 2, 4, 6, 10, and 15

  13. Area Under the Curve (AUC) in Virus Titer

    AUC was calculated using the trapezoidal method. Participants with a positive virus titer on Day 1 were included in this analysis. The lower limit was defined as 0.75 log10 TCID50/mL for flu A and flu B. If a participant was infected with multiple virus types, the sum of those virus titers was used for analysis. log10 TCID50/mL\*h=log10 TCID50 per milliliter-hours. Analyses were done with use of samples from respiratory swabs.

    Time frame: Up to Day 10

  14. AUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs

    AUC in virus RNA (RT-PCR) AUC was calculated using the trapezoidal method. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. If a participant was infected with multiple virus types, the sum of the amount of virus RNA was used for analysis. log10 vp/mL\*h=log 10 virus particles per milliliter-hours.

    Time frame: Up to Day 10

  15. Plasma Concentrations of S-033447 (Active Metabolite)

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Post-dose on Days 1, 2, 4, and 6

  16. Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) of S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Post-dose on Days 1, 2, 4, and 6

  17. Maximum Observed Concentration (Cmax) of S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Post-dose on Days 1, 2, 4, and 6

  18. Time of Maximum Observed Concentration (Tmax) of S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Post-dose on Days 1, 2, 4, and 6

  19. Elimination Half-life (t1/2) of S-033447

    S-033447 is an active metabolite of baloxavir marboxil.

    Time frame: Post-dose on Days 1, 2, 4, and 6

  20. Percentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene

    Sanger sequencing of the influenza PA gene was performed to evaluate the incidence of polymorphic and treatment-emergent amino acid substitutions in baloxavir-treated participants with evaluable virus.

    Time frame: Up to Day 29

  21. Drug Susceptibility in Participants With Evaluable Virus

    Drug susceptibility of the influenza virus, the 50% effective concentration (EC50) of baloxavir was measured by the ViroSpot™ assay using baseline swab samples for participants who received baloxavir marboxil. EC50 values were compared with EC50 values of reference strains and the respective ratio (EC50 / EC50 reference) was reported. The following influenza virus vaccines strains from the 2024/25 Northern hemisphere season were used as references: A/Wisconsin/67/2022 (H1N1) pdm09-like virus, A/Massachusetts/18/2022 (H3N2)-like virus and B/Austria/1359417/2021-like virus (B/Victoria/2/87 lineage). In the absence of established thresholds for baloxavir, reduced susceptibility was defined according to the WHO criteria for neurainidase inhibitor (NAI) as fold-changes in EC50 (EC50 / EC50 of reference) \> 10 for influenza A and \> 5 for influenza B viruses.

    Time frame: Up to Day 29

  22. Percentage of Participants With Responses to Palatability and Acceptability Questionnaire

    A two-question palatability and acceptability questionnaire was used to record palatability and acceptability. Palatability of baloxavir marboxil was evaluated by response to the following question, "How was the taste of the medicine? Please pick the face that best matches how you/the child felt about the taste". The responses ranged from: like very much, like a little, not sure, dislike a little, or dislike very much. Acceptability of baloxavir marboxil was evaluated by response to the following question, "Would you/the child be happy to take the medicine again?" The responses ranged from: Yes, No, or Not sure. The questionnaire was completed as soon as possible after swallowing the baloxavir marboxil drug solution on Day 1. Percentages have been rounded off.

    Time frame: On Day 1

07

Results

Posted Apr 27, 2026

Participant flow

A total of 100 participants aged 1 to \<12 years with influenza symptoms were randomized in the study at 16 investigative sites in China from 27 October 2024 to 08 May 2025.

Participant flow — Overall Study
MilestoneBaloxavir MarboxilOseltamivir
Started6733
Safety analysis set (sas)6633
Full analysis set-infected participants (fasi)6131
Completed6432
Not completed31
Withdrew: Withdrawal by subject30
Withdrew: Reason not specified01

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, was a congenital anomaly or birth defect.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsBaloxavir MarboxilOseltamivir
AEs2412
SAEs20
SecondaryTime to Alleviation of Influenza Signs and Symptoms (TTAS)

TTAS was defined as the length of time taken from start of treatment to point at which all of following criteria were met \& remained so for at least 21.5 hours: * Score of 0 (no problem) or 1 (minor problem) for cough \& nasal symptoms (Items 14 \& 15 of Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to following question- "Since last assessment has participant been able to return to day care/school, or resume his/her normal daily activity in same way as performed prior to developing flu?"; * Return to afebrile state (tympanic temperature ≤ 37.2 degree Celsius \[°C\]). Median time was estimated using Kaplan-Meier (K-M) method.

Time frame:
Up to Day 15
Reported as:
Median · hours
Time to Alleviation of Influenza Signs and Symptoms (TTAS)
hoursBaloxavir MarboxilOseltamivir
Time to Alleviation of Influenza Signs and Symptoms (TTAS)126.1 (92.2 to 141.1)119.5 (90.5 to 160.0)
SecondaryDuration of Fever

Duration of fever was defined as the length of time from start of treatment to return to afebrile state (tympanic temperature ≤ 37.2°C) and remaining so for at least 21.5 hours. Participants who were afebrile at baseline (tympanic temperature ≤ 37.2 °C) or whose body temperature was not collected were excluded from the analysis. Median time was estimated using K-M method.

Time frame:
Up to Day 15
Reported as:
Median · hours
Duration of Fever
hoursBaloxavir MarboxilOseltamivir
Duration of Fever28.3 (23.3 to 38.9)36.1 (29.3 to 44.0)
SecondaryDuration of Symptoms

Duration of symptoms was defined as the length of time from start of treatment to alleviation of all symptoms as defined by a score of 0 (no problem) or 1 (minor problem) and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point. Median time was estimated using K-M method.

Time frame:
Up to Day 15
Reported as:
Median · hours
Duration of Symptoms
hoursBaloxavir MarboxilOseltamivir
Duration of Symptoms43.9 (35.0 to 76.6)51.9 (34.5 to 71.0)
SecondaryTime to Return to Normal Health and Activity Based on the CARIFS Questionnaire

Time to return to normal health and activity was defined as time from start of treatment to normal health and activity. Normal health \& activity was identified by a 'yes' response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his/her normal daily activity in the same way as performed prior to developing the flu?". Median time was estimated using K-M method.

Time frame:
Up to Day 15
Reported as:
Median · hours
Time to Return to Normal Health and Activity Based on the CARIFS Questionnaire
hoursBaloxavir MarboxilOseltamivir
Time to Return to Normal Health and Activity Based on the CARIFS Questionnaire126.0 (81.8 to 137.8)115.3 (88.4 to 136.7)
SecondaryNumber of Participants With Influenza-related Complications

Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Influenza-related Complications
ParticipantsBaloxavir MarboxilOseltamivir
Number of Participants With Influenza-related Complications20
SecondaryPercentage of Participants Requiring Antibiotics for Influenza-related Complications

Influenza-related complications included death, hospitalization, radiologically-confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, and myositis. Percentages have been rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Antibiotics for Influenza-related Complications
percentage of participantsBaloxavir MarboxilOseltamivir
Percentage of Participants Requiring Antibiotics for Influenza-related Complications1.60
SecondaryTime to Cessation of Viral Shedding by Virus Titer

Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of study treatment and the first time when the influenza virus titer was below the lower limit of detection (LLoD) (0.75 log10 tissue culture infectious dose \[TCID\] 50/milliliters \[mL\]). Participants whose virus ribonucleic acid (RNA) did not reach the limit by the last observation timepoint were treated as censored at that timepoint. Median time was estimated using K-M method.

Time frame:
Up to Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Virus Titer
hoursBaloxavir MarboxilOseltamivir
Time to Cessation of Viral Shedding by Virus Titer23.2 (21.9 to 24.4)100.7 (70.9 to 120.3)
SecondaryTime to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs

Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of study treatment and the first time when the virus RNA by RT-PCR qualitative result is below the LLoD (qualitative assessment). For the participants with multiple virus types, time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result is negative for all virus types. Participants whose virus RNA did not reach the limit by the last observation timepoint were censored at that timepoint. Median time was estimated using K-M method.

Time frame:
Up to Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs
hoursBaloxavir MarboxilOseltamivir
Time to Cessation of Viral Shedding by Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) Using Samples From Respiratory Swabs218.4 (214.8 to 242.7)238.6 (214.8 to NA)
SecondaryChange From Baseline in Influenza Virus Titer Over Time Using Samples From Respiratory Swabs

Change from baseline in influenza virus titer (log10 TCID50/mL) on Days 2, 4, 6, 10, and 15 are presented. Influenza virus titer on specified time points was analysed with use of samples from respiratory swabs. If influenza virus titer was less than the lower limit of quantification (LLoQ), the virus titer was imputed as LLoQ - 0.001 (0.749 log10 TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.

Time frame:
Baseline, Days 2, 4, 6, 10, and 15
Reported as:
Mean · log10 TCID 50/mL
Change From Baseline in Influenza Virus Titer Over Time Using Samples From Respiratory Swabs
log10 TCID 50/mLBaloxavir MarboxilOseltamivir
Baseline4.41 ± 1.325.21 ± 1.11
Change at Day 2-3.61 ± 1.45-3.11 ± 1.34
Change at Day 4-3.65 ± 1.35-3.06 ± 1.85
Change at Day 6-3.72 ± 1.43-4.30 ± 1.13
Change at Day 10-3.95 ± 1.28-4.50 ± 1.09
Change at Day 15—-5.50 ± NA
SecondaryChange From Baseline in Amount of Virus RNA (RT-PCR) at Each Timepoint Using Samples From Respiratory Swabs

If the amount of virus RNA was less than the LLoQ, the amount of virus RNA was imputed as LLoQ - 0.001 (2.79 log10 vp/mL for influenza A and 2.63 log10 vp/mL for influenza B). If a participant was infected with multiple virus types, the sum of those amounts of virus RNA was used for analysis. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. log10 vp/mL=log 10 virus particles per milliliter.

Time frame:
Baseline, Days 2, 4, 6, 10, and 15
Reported as:
Mean · log10 vp/mL
Change From Baseline in Amount of Virus RNA (RT-PCR) at Each Timepoint Using Samples From Respiratory Swabs
log10 vp/mLBaloxavir MarboxilOseltamivir
Baseline7.00 ± 1.257.43 ± 1.20
Change at Day 2-1.76 ± 1.37-1.37 ± 0.77
Change at Day 4-2.79 ± 1.39-1.82 ± 1.71
Change at Day 6-2.92 ± 1.44-2.81 ± 1.69
Change at Day 10-4.04 ± 1.34-3.70 ± 1.28
Change at Day 15—-4.64 ± NA
SecondaryPercentage of Participants With Positive Influenza Virus Titer Over Time

Percentage of participants with positive influenza virus titer was defined as the percentage of participants whose influenza virus titer was not less than the LLoD (0.75 log10 TCID50/mL) or positive among those assessed for influenza virus titer on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants with a positive influenza virus titer on Day 1 were be included in this analysis. Percentages have been rounded off.

Time frame:
Baseline, Days 2, 4, 6, 10, and 15
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer Over Time
percentage of participantsBaloxavir MarboxilOseltamivir
Baseline100.0100.0
Day 211.185.7
Day 46.065.4
Day 610.013.6
Day 103.40
Day 15—0
SecondaryPercentage of Participants Positive by RT-PCR at Each Timepoint Using Samples From Respiratory Swabs

Percentage of participants with positive influenza virus titer was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on specified timepoints. Analyses were done with use of samples from respiratory swabs. Participants positive for virus RNA by RT-PCR on Day 1 were be included in this analysis. Percentages have been rounded off.

Time frame:
Baseline, Days 2, 4, 6, 10, and 15
Reported as:
Number · percentage of participants
Percentage of Participants Positive by RT-PCR at Each Timepoint Using Samples From Respiratory Swabs
percentage of participantsBaloxavir MarboxilOseltamivir
Baseline100.0100.0
Day 298.3100.0
Day 491.496.4
Day 682.792.0
Day 1051.759.3
Day 15—100.0
SecondaryArea Under the Curve (AUC) in Virus Titer

AUC was calculated using the trapezoidal method. Participants with a positive virus titer on Day 1 were included in this analysis. The lower limit was defined as 0.75 log10 TCID50/mL for flu A and flu B. If a participant was infected with multiple virus types, the sum of those virus titers was used for analysis. log10 TCID50/mL\*h=log10 TCID50 per milliliter-hours. Analyses were done with use of samples from respiratory swabs.

Time frame:
Up to Day 10
Reported as:
Mean · log10 TCID 50/mL*h
Area Under the Curve (AUC) in Virus Titer
log10 TCID 50/mL*hBaloxavir MarboxilOseltamivir
Area Under the Curve (AUC) in Virus Titer-536.09 ± 312.86-610.11 ± 414.54
SecondaryAUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs

AUC in virus RNA (RT-PCR) AUC was calculated using the trapezoidal method. Participants positive for virus RNA by RT-PCR on Day 1 were included in this analysis. If a participant was infected with multiple virus types, the sum of the amount of virus RNA was used for analysis. log10 vp/mL\*h=log 10 virus particles per milliliter-hours.

Time frame:
Up to Day 10
Reported as:
Mean · log10 vp/mL*h
AUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs
log10 vp/mL*hBaloxavir MarboxilOseltamivir
AUC in the Amount of Virus RNA (RT-PCR) Using Samples From Respiratory Swabs-390.08 ± 263.39-388.13 ± 325.99
SecondaryPlasma Concentrations of S-033447 (Active Metabolite)

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Post-dose on Days 1, 2, 4, and 6
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of S-033447 (Active Metabolite)
nanograms per milliliter (ng/mL)Baloxavir Marboxil
Post-dose Day 175.49 ± 77.283
Post-dose Day 2125.25 ± 35.225
Post-dose Day 443.15 ± 24.872
Post-dose Day 615.86 ± 9.169
SecondaryArea Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) of S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Post-dose on Days 1, 2, 4, and 6
Reported as:
Mean · nanograms-hour per milliliter (ng*h/mL)
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) of S-033447
nanograms-hour per milliliter (ng*h/mL)Baloxavir Marboxil
Bodyweight <20 kg, Dose=2 mg/kg9550 ± 4230
Bodyweight ≥20 kg, Dose=40 mg11800 ± 4870
SecondaryMaximum Observed Concentration (Cmax) of S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Post-dose on Days 1, 2, 4, and 6
Reported as:
Mean · ng/mL
Maximum Observed Concentration (Cmax) of S-033447
ng/mLBaloxavir Marboxil
Bodyweight <20 kg, Dose=2 mg/kg182 ± 68.2
Bodyweight ≥20 kg, Dose=40 mg159 ± 72.2
SecondaryTime of Maximum Observed Concentration (Tmax) of S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Post-dose on Days 1, 2, 4, and 6
Reported as:
Median · hours
Time of Maximum Observed Concentration (Tmax) of S-033447
hoursBaloxavir Marboxil
Bodyweight <20 kg, Dose=2 mg/kg3.75 (1.00 to 15.0)
Bodyweight ≥20 kg, Dose=40 mg4.25 (1.00 to 15.5)
SecondaryElimination Half-life (t1/2) of S-033447

S-033447 is an active metabolite of baloxavir marboxil.

Time frame:
Post-dose on Days 1, 2, 4, and 6
Reported as:
Median · hours
Elimination Half-life (t1/2) of S-033447
hoursBaloxavir Marboxil
Bodyweight <20 kg, Dose=2 mg/kg30.0 (21.8 to 56.0)
Bodyweight ≥20 kg, Dose=40 mg45.8 (31.0 to 91.4)
SecondaryPercentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene

Sanger sequencing of the influenza PA gene was performed to evaluate the incidence of polymorphic and treatment-emergent amino acid substitutions in baloxavir-treated participants with evaluable virus.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene
percentage of participantsInfluenza Type A/H1_2009Influenza Type A/H3N2Influenza Type B
Percentage of Participants With Polymorphic and Treatment-emergent Amino Acid Substitutions in the Polymerase Acidic (PA) Gene10.64 (3.55 to 23.10)100.00 (15.81 to 100.00)0.00 (0.00 to 84.19)
SecondaryDrug Susceptibility in Participants With Evaluable Virus

Drug susceptibility of the influenza virus, the 50% effective concentration (EC50) of baloxavir was measured by the ViroSpot™ assay using baseline swab samples for participants who received baloxavir marboxil. EC50 values were compared with EC50 values of reference strains and the respective ratio (EC50 / EC50 reference) was reported. The following influenza virus vaccines strains from the 2024/25 Northern hemisphere season were used as references: A/Wisconsin/67/2022 (H1N1) pdm09-like virus, A/Massachusetts/18/2022 (H3N2)-like virus and B/Austria/1359417/2021-like virus (B/Victoria/2/87 lineage). In the absence of established thresholds for baloxavir, reduced susceptibility was defined according to the WHO criteria for neurainidase inhibitor (NAI) as fold-changes in EC50 (EC50 / EC50 of reference) \> 10 for influenza A and \> 5 for influenza B viruses.

Time frame:
Up to Day 29
Reported as:
Mean · ratio
Drug Susceptibility in Participants With Evaluable Virus
ratioBaloxavir Marboxil
Virus Subtype B4.224 ± 0.3019
Virus Subtype H1_20092.226 ± 0.6764
Virus Subtype_H31.904 ± 1.5768
SecondaryPercentage of Participants With Responses to Palatability and Acceptability Questionnaire

A two-question palatability and acceptability questionnaire was used to record palatability and acceptability. Palatability of baloxavir marboxil was evaluated by response to the following question, "How was the taste of the medicine? Please pick the face that best matches how you/the child felt about the taste". The responses ranged from: like very much, like a little, not sure, dislike a little, or dislike very much. Acceptability of baloxavir marboxil was evaluated by response to the following question, "Would you/the child be happy to take the medicine again?" The responses ranged from: Yes, No, or Not sure. The questionnaire was completed as soon as possible after swallowing the baloxavir marboxil drug solution on Day 1. Percentages have been rounded off.

Time frame:
On Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Responses to Palatability and Acceptability Questionnaire
percentage of participantsBaloxavir Marboxil
Palatability: Like Very Much39.4
Palatability: Like a Little31.8
Palatability: Not Sure6.1
Palatability: Dislike a Little18.2
Palatability: Dislike Very Much4.5
Acceptability: Yes65.2
Acceptability: No16.7
Acceptability: Not Sure18.2

Adverse events

Collected over Up to Day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil0/66 (0%)2/66 (3%)14/66 (21.2%)
Oseltamivir0/33 (0%)0/33 (0%)10/33 (30.3%)
Most frequent serious events
Most frequent serious events
EventBaloxavir MarboxilOseltamivir
PneumoniaInfections and infestations1/660/33
Pneumonia mycoplasmalInfections and infestations1/660/33
Most frequent other events
Most frequent other events
EventBaloxavir MarboxilOseltamivir
VomitingGastrointestinal disorders3/666/33
BronchitisInfections and infestations5/660/33
Functional gastrointestinal disorderGastrointestinal disorders2/662/33
RhinitisInfections and infestations0/662/33
Upper respiratory tract infectionInfections and infestations4/661/33

Baseline characteristics

FAS included all randomized participants, with participants grouped according to the treatment assigned.

Age, Continuous
Age, Continuous(years)Baloxavir MarboxilOseltamivirTotal
Mean5.1 ± 2.555.3 ± 2.755.2 ± 2.61
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir MarboxilOseltamivirTotal
Female341145
Male332255
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baloxavir MarboxilOseltamivirTotal
Hispanic or Latino000
Not Hispanic or Latino6733100
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baloxavir MarboxilOseltamivirTotal
American Indian or Alaska Native000
Asian6733100
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • The First People's Hospital of Changde
    Changde, DUMMY_VALUE, China
  • Peoples Hospital of Hunan Province
    Changsha, 410007, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, 610091, China
  • Chongqing University Jiangjin Hospital
    Chongqing, 402260, China
  • Childern's Hospital of Chongqing Medical University
    Chongqing, DUMMY_VALUE, China
  • Hebei Petro China Central Hospital
    Langfang, 065000, China
  • Liaocheng people's Hospital
    Liaocheng, 252000, China
  • Linfen Central Hospital
    Linfen, 041000, China
  • Liuzhou People's Hospital
    Liuzhou, 545006, China
  • Ningbo Women and Children's Hospital
    Ningbo, 315021, China
  • Sanmenxia Central Hospital
    Sanmenxia, DUMMY_VALUE, China
  • The Third People's Hospital of Hainan Province
    Sanya, 572000, China
  • The Second Affiliated Hospital of Shantou University Medical College
    Shantou, 515051, China
  • The First Affiliated Hospital, Shaoyang University
    Shaoyang, DUMMY_VALUE, China
  • University of Chinese Academy of Sciences Shenzhen Hospital
    Shenzhen, 518107, China
  • Xiamen Maternal and Child Health Hospital
    Xiamen, 361001, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2025, 6 months.

Results were first posted in Apr 2026, 11 months after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Oct 27, 2024
Primary completionActual
May 8, 2025
CompletionActual
May 8, 2025
Results first posted
Apr 27, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06774859
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Oct 27, 2024
Primary completion
May 8, 2025
Completion
May 8, 2025
Results posted
Apr 27, 2026
Last update
Apr 27, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion